Literature DB >> 18344704

Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers.

Angela R Bradbury1,2, Comfort N Ibe1,2, James J Dignam3, Shelly A Cummings1,2, Marion Verp1,4, Melody A White1,2, Grazia Artioli5, Laura Dudlicek1,2, Olufunmilayo I Olopade1,2.   

Abstract

PURPOSE: To evaluate prophylactic salpingo-oophorectomy uptake and timing among BRCA1/2 mutation carriers in a cancer risk assessment program.
METHODS: Clinical records of female BRCA1/2 mutation carriers who received cancer genetic counseling between 1996 and 2003 were reviewed to determine the completion and the timing of prophylactic salpingo-oophorectomy. Logistic regression models evaluated associations between subject characteristics and surgery. Survival analysis methods were used to estimate the distribution of time to surgery.
RESULTS: Among 88 women, 70% underwent prophylactic salpingo-oophorectomy. Prophylactic salpingo-oophorectomy was associated with older age, white race, having children, and a family history of ovarian cancer. Many women waited more than 12 months to undergo surgery and some delayed by several years. Younger age and not having children were associated with delays to surgery.
CONCLUSION: Prophylactic salpingo-ooporectomy is an acceptable risk reduction measure for many BRCA1/2 mutation carriers. Some women make this decision many years after genetic testing. Continued discussion of the risks and benefits of risk reduction options may facilitate the uptake of recommended risk reduction interventions among BRCA mutation carriers.

Entities:  

Mesh:

Year:  2008        PMID: 18344704      PMCID: PMC4199586          DOI: 10.1097/GIM.0b013e318163487d

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  32 in total

1.  Breast cancer screening practices among black, Hispanic, and white women: reassessing differences.

Authors:  D N Pearlman; W Rakowski; B Ehrich; M A Clark
Journal:  Am J Prev Med       Date:  1996 Sep-Oct       Impact factor: 5.043

2.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Authors:  A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton
Journal:  Am J Hum Genet       Date:  2003-04-03       Impact factor: 11.025

3.  Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy.

Authors:  Sheri A Babb; Elizabeth M Swisher; Hope N Heller; Alison J Whelan; David G Mutch; Thomas J Herzog; Janet S Rader
Journal:  J Genet Couns       Date:  2002-04       Impact factor: 2.537

4.  Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.

Authors:  E J Meijers-Heijboer; L C Verhoog; C T Brekelmans; C Seynaeve; M M Tilanus-Linthorst; A Wagner; L Dukel; P Devilee; A M van den Ouweland; A N van Geel; J G Klijn
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

5.  Laparoscopic management of women with a family history of ovarian cancer.

Authors:  G H Eltabbakh; M S Piver; R E Hempling; F O Recio; T Paczos
Journal:  J Surg Oncol       Date:  1999-09       Impact factor: 3.454

6.  Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Authors:  Anne Uyei; Susan K Peterson; Julie Erlichman; Kristine Broglio; Sandra Yekell; Kathkeen Schmeler; Karen Lu; Funda Meric-Bernstam; Chris Amos; Louise Strong; Banu Arun
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

7.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

8.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Authors:  Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

9.  Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred.

Authors:  Anita Yeomans Kinney; Sara Ellis Simonsen; Bonnie Jeanne Baty; Diptasri Mandal; Susan L Neuhausen; Kate Seggar; Richard Holubkov; Lindsey Bloor; Ken Smith
Journal:  J Genet Couns       Date:  2006-08       Impact factor: 2.537

10.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

View more
  37 in total

1.  Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?

Authors:  Chanita Hughes Halbert; Jill E Stopfer; Jasmine McDonald; Benita Weathers; Aliya Collier; Andrea B Troxel; Susan Domchek
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

Review 2.  Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.

Authors:  Roi Tschernichovsky; Annekathryn Goodman
Journal:  Oncologist       Date:  2017-03-17

3.  Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.

Authors:  Dongwon Kim; Eunyoung Kang; Euijun Hwang; Young Sun; Yoonsun Hwang; Cha Kyong Yom; Kidong Kim; Jae Hong No; Yong-Beom Kim; Sung-Won Kim
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

4.  Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.

Authors:  Se Ik Kim; Myong Cheol Lim; Dong Ock Lee; Sun-Young Kong; Sang-Soo Seo; Sokbom Kang; Eun Sook Lee; Sang-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-05       Impact factor: 4.553

5.  Before it catches the eye….

Authors:  Marian J Mourits; Geertruida H de Bock
Journal:  Ann Transl Med       Date:  2019-12

6.  Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.

Authors:  Hidetaka Nomura; Masayuki Sekine; Shiro Yokoyama; Masami Arai; Takayuki Enomoto; Nobuhiro Takeshima; Seigo Nakamura
Journal:  Int J Clin Oncol       Date:  2019-05-04       Impact factor: 3.402

7.  The process of deciding about prophylactic surgery for breast and ovarian cancer: Patient questions, uncertainties, and communication.

Authors:  Robert Klitzman; Wendy Chung
Journal:  Am J Med Genet A       Date:  2010-01       Impact factor: 2.802

8.  Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers.

Authors:  Anita Caruso; Cristina Vigna; Bruna Marozzo; Fabio M Sega; Isabella Sperduti; Francesco Cognetti; Antonella Savarese
Journal:  J Exp Clin Cancer Res       Date:  2009-12-21

9.  Deleterious BRCA1/2 mutations in an urban population of Black women.

Authors:  Filipa Lynce; Karen Lisa Smith; Julie Stein; Tiffani DeMarco; Yiru Wang; Hongkun Wang; Melissa Fries; Beth N Peshkin; Claudine Isaacs
Journal:  Breast Cancer Res Treat       Date:  2015-08-07       Impact factor: 4.872

10.  Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.

Authors:  Bettina Meiser; Melanie A Price; Phyllis N Butow; Janan Karatas; Judy Wilson; Louise Heiniger; Brandi Baylock; Margaret Charles; Sue-Anne McLachlan; Kelly-Anne Phillips
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.